Eledon Pharmaceuticals Inc
$ 3.69
6.65%
07 Aug - close price
- Market Cap 284,823,000 USD
- Current Price $ 3.69
- High / Low $ 3.70 / 3.44
- Stock P/E N/A
- Book Value 1.32
- EPS -0.82
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.73 %
- 52 Week High 4.60
- 52 Week Low 1.35
About
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
Analyst Target Price
$9.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-19 | 2025-11-14 | 2025-08-14 | 2025-05-14 | 2025-03-20 | 2024-11-12 | 2024-08-19 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.33 | -0.1 | -0.21 | -0.13 | -0.08 | -0.9456 | -0.32 | -1.06 | -0.34 | -0.29 | -0.35 | -0.4 |
| Estimated EPS | -0.26 | -0.2 | -0.25 | -0.23 | -0.3 | -0.3267 | -0.31 | -0.32 | -0.33 | -0.39 | -0.41 | -0.45 |
| Surprise | -0.07 | 0.1 | 0.04 | 0.1 | 0.22 | -0.6189 | -0.01 | -0.74 | -0.01 | 0.1 | 0.06 | 0.05 |
| Surprise Percentage | -26.9231% | 50% | 16% | 43.4783% | 73.3333% | -189.4399% | -3.2258% | -231.25% | -3.0303% | 25.641% | 14.6341% | 11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELDN
2026-08-06 17:41:20
Eledon Pharmaceuticals announced that all 12 patients in an investigator-initiated trial achieved insulin independence following islet cell transplantation with tegoprubart-based immunosuppression. These patients, with long-standing type 1 diabetes, no longer required exogenous insulin therapy and showed significant improvement in hemoglobin A1C levels without severe hypoglycemic episodes or common side effects associated with other immunosuppressants. The positive results have led to Eledon's stock surging and plans to seek regulatory guidance from the FDA for tegoprubart later this year.
2026-07-31 14:09:55
Vanguard Capital Management has disclosed a 5.05% passive ownership stake in Eledon Pharmaceuticals (ELDN) through a Schedule 13G SEC filing. This stake amounts to 3,898,446 shares, with Vanguard holding sole voting power over 481,223 shares and sole dispositive power over all 3,898,446 shares. The filing aggregates holdings from various Vanguard funds and managed accounts, indicating a passive investment purpose rather than an intent to control the company.
2026-07-29 07:42:04
Eledon Pharmaceuticals Inc (ELDN) currently holds a financial score of 5.85, ranking 311 out of 385 in the Biotechnology & Medical Research industry, indicating weak financial status and low operating efficiency. The analysis highlights that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company. ELDN's stock closed at $3.310, down 2.65%, with a market cap of $251.07 million.
2026-07-28 09:41:10
This article provides a detailed quarterly and annual cash flow statement for Eledon Pharmaceuticals Inc (ELDN), allowing users to evaluate the company's financial health and stability. It includes data on operating, investing, and financing cash flows, along with frequently asked questions defining these financial metrics and their relevance. The information is presented to help investors understand the company's cash generation and usage.
2026-07-28 09:39:18
This article from TradingKey attempts to provide a revenue breakdown for Eledon Pharmaceuticals Inc (ELDN), including business segments and regional contributions. However, it explicitly states that the relevant data have not yet been disclosed by the company, rendering the requested information unavailable. The page displays current stock metrics for ELDN.
2026-07-28 00:11:30
This article details the shareholder structure of Eledon Pharmaceuticals Inc (ELDN), listing major individual and institutional investors and their proportional holdings. It also provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with specific changes in holdings. Additionally, it mentions related ETFs with their respective proportions in ELDN.
